Find Indapamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

186RELATED EXCIPIENT COMPANIES

297EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 26807-65-8, Noranat, Veroxil, Tertensif, Lozol, Indaflex
Molecular Formula
C16H16ClN3O3S
Molecular Weight
365.8  g/mol
InChI Key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
FDA UNII
F089I0511L

Indapamide
A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
Indapamide is a Thiazide-like Diuretic. The physiologic effect of indapamide is by means of Increased Diuresis.
1 2D Structure

Indapamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
2.1.2 InChI
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
2.1.3 InChI Key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
2.2 Other Identifiers
2.2.1 UNII
F089I0511L
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Metindamide

2. S 1520

3. S-1520

4. S1520

5. Se 1520

6. Se-1520

7. Se1520

2.3.2 Depositor-Supplied Synonyms

1. 26807-65-8

2. Noranat

3. Veroxil

4. Tertensif

5. Lozol

6. Indaflex

7. Arifon

8. Fludex

9. Indamol

10. Bajaten

11. Ipamix

12. Tandix

13. Natrilix

14. Damide

15. Pressurai

16. Indapamida

17. Indapamidum

18. Natrix

19. Indapamidum [inn-latin]

20. Indapamida [inn-spanish]

21. Se-1520

22. Flupamid

23. Indamide

24. 1-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline

25. Fludin

26. Lorvas

27. 4-chloro-n-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide

28. S-1520

29. Benzamide, 3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)-

30. 4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide

31. Indapamide (lozol)

32. Flubest

33. 4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)-3-sulfamoylbenzamide

34. Metindamide

35. Cormil

36. Nsc-757075

37. N-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline

38. Mls000028554

39. Chebi:5893

40. 26807-65-8(free Base)

41. Kyd-041

42. Benzamide, 4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoyl-

43. F089i0511l

44. Ncgc00018172-03

45. Smr000058829

46. 4-chloro-n-(2-methylindolin-1-yl)-3-sulfamoylbenzamide

47. Dsstox_cid_24633

48. Dsstox_rid_80366

49. Dsstox_gsid_44633

50. Se 1520

51. Rhc 2555

52. Usv 2555

53. Natrix (tn)

54. Lozol (tn)

55. Sr-01000003079

56. Einecs 248-012-7

57. Mfcd00079375

58. Brn 1604026

59. Unii-f089i0511l

60. Hypen Sr

61. 3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)benzamide

62. Indapamide [usan:usp:inn:ban:jan]

63. Spectrum_000917

64. Indapamide [mi]

65. Opera_id_110

66. Indapamide [inn]

67. Indapamide [jan]

68. Prestwick3_000220

69. Spectrum2_000980

70. Spectrum3_000467

71. Spectrum4_000017

72. Spectrum5_000866

73. Indapamide [usan]

74. S1520

75. Indapamide [vandf]

76. Chembl406

77. Indapamide (jp17/usp)

78. Indapamide [mart.]

79. Indapamide [usp-rs]

80. Indapamide [who-dd]

81. Schembl41303

82. Bspbio_000239

83. Bspbio_002174

84. Kbiogr_000393

85. Kbioss_001397

86. 5-20-06-00348 (beilstein Handbook Reference)

87. Mls001148152

88. Mls002222229

89. Mls006011900

90. Divk1c_000508

91. Spectrum1500349

92. Spbio_001019

93. Bpbio1_000263

94. Gtpl7203

95. Dtxsid7044633

96. Indapamide [ep Impurity]

97. Indapamide [orange Book]

98. Bdbm25901

99. Hms501j10

100. Kbio1_000508

101. Kbio2_001397

102. Kbio2_003965

103. Kbio2_006533

104. Kbio3_001394

105. Indapamide [ep Monograph]

106. Ninds_000508

107. Hms1920f19

108. Hms2090m16

109. Hms2091n07

110. Hms2095l21

111. Hms2231g13

112. Hms3259c14

113. Hms3369j20

114. Hms3655e06

115. Hms3712l21

116. Hms3748k05

117. Indapamide [usp Monograph]

118. Pharmakon1600-01500349

119. Indapamide 1.0 Mg/ml In Methanol

120. Amy31945

121. Bcp04140

122. Hy-b0259

123. Tox21_110775

124. Tox21_113182

125. Tox21_302687

126. Ccg-40198

127. Nsc757075

128. S1730

129. Stl257105

130. Stl455045

131. 3-(aminosulfonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)benzamide

132. Akos015888148

133. Tox21_110775_1

134. Ab03037

135. Ac-2073

136. Db00808

137. Ks-5219

138. Nc00568

139. Nsc 757075

140. Benzamide, 3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-l-yl)-

141. Idi1_000508

142. Ncgc00018172-02

143. Ncgc00018172-04

144. Ncgc00018172-06

145. Ncgc00018172-08

146. Ncgc00018172-09

147. Ncgc00089727-02

148. Ncgc00089727-03

149. Ncgc00256884-01

150. Sbi-0051415.p003

151. Db-047020

152. Ab00052021

153. I0730

154. Sw198686-2

155. A23574

156. D00345

157. Ab00052021-14

158. Ab00052021-15

159. Ab00052021_16

160. Ab00052021_17

161. 807i658

162. Indapamide, Analytical Standard, For Drug Analysis

163. J-016554

164. Q1078392

165. Sr-01000003079-2

166. Sr-01000003079-3

167. Brd-a95869247-001-04-6

168. Brd-a95869247-001-14-5

169. Z2786158257

170. Indapamide, British Pharmacopoeia (bp) Reference Standard

171. Indapamide, European Pharmacopoeia (ep) Reference Standard

172. Indapamide, United States Pharmacopeia (usp) Reference Standard

173. 3-aminosulfonyl-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)benzamide

174. 4-chloro-3-aminosulphonyl-n-(2,3-dihydro2-methyl-1h-indol-1-yl)benzamide

175. Indapamide, Pharmaceutical Secondary Standard; Certified Reference Material

176. 3-(aminosulphonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1--yl)benzamide

177. 3-(aminosulphonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)benzamide

178. 4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)-3-sulfamoylbenzenecarboximidic Acid

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 365.8 g/mol
Molecular Formula C16H16ClN3O3S
XLogP32.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count3
Exact Mass365.0600902 g/mol
Monoisotopic Mass365.0600902 g/mol
Topological Polar Surface Area101 Ų
Heavy Atom Count24
Formal Charge0
Complexity580
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameIndapamide
PubMed HealthIndapamide (By mouth)
Drug ClassesCardiovascular Agent
Drug LabelIndapamide is an oral antihypertensive/diuretic. Its molecule contains both a polar sulfamoyl chlorobenzamide moiety and a lipid-soluble methylindoline moiety. It differs chemically from the thiazides in that it does not possess the thiazide ring sys...
Active IngredientIndapamide
Dosage FormTablet
RouteOral
Strength2.5mg; 1.25mg
Market StatusPrescription
CompanyMylan Pharms; Ivax Sub Teva Pharms; Actavis Elizabeth; Mylan

2 of 2  
Drug NameIndapamide
PubMed HealthIndapamide (By mouth)
Drug ClassesCardiovascular Agent
Drug LabelIndapamide is an oral antihypertensive/diuretic. Its molecule contains both a polar sulfamoyl chlorobenzamide moiety and a lipid-soluble methylindoline moiety. It differs chemically from the thiazides in that it does not possess the thiazide ring sys...
Active IngredientIndapamide
Dosage FormTablet
RouteOral
Strength2.5mg; 1.25mg
Market StatusPrescription
CompanyMylan Pharms; Ivax Sub Teva Pharms; Actavis Elizabeth; Mylan

4.2 Drug Indication

Indapamide is a diuretic indicated for use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension. It may also be used to treat fluid and salt retention associated with congestive heart failure.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Classified as a sulfonamide diuretic, indapamide is an effective antihypertensive agent and by extension, has shown efficacy in the prevention of target organ damage. Administration of indapamide produces water and electrolyte loss, with higher doses associated with increased diuresis. Severe and clinically significant electrolyte disturbances may occur with indapamide use - for example, hypokalemia resulting from renal potassium loss may lead to QTc prolongation. Further electrolyte imbalances may occur due to renal excretion of sodium, chloride, and magnesium. Other indapamide induced changes include increases in plasma renin and aldosterone, and reduced calcium excretion in the urine. In many studies investigating the effects of indapamide in both non-diabetic and diabetic hypertensive patients, glucose tolerance was not significantly altered. However, additional studies are necessary to assess the long term metabolic impacts of indapamide, since thiazide related impaired glucose tolerance can take several years to develop in non-diabetic patients.


5.2 MeSH Pharmacological Classification

Diuretics

Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)


Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


Sodium Chloride Symporter Inhibitors

Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA. (See all compounds classified as Sodium Chloride Symporter Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
INDAPAMIDE
5.3.2 FDA UNII
F089I0511L
5.3.3 Pharmacological Classes
Thiazide-like Diuretic [EPC]; Increased Diuresis [PE]
5.4 ATC Code

C03BA11

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


C - Cardiovascular system

C03 - Diuretics

C03B - Low-ceiling diuretics, excl. thiazides

C03BA - Sulfonamides, plain

C03BA11 - Indapamide


5.5 Absorption, Distribution and Excretion

Absorption

The bioavailability of indapamide is virtually complete after an oral dose and is unaffected by food or antacids. Indapamide is highly lipid-soluble due to its indoline moiety - a characteristic that likely explains why indapamides renal clearance makes up less than 10% of its total systemic clearance. The Tmax occurs approximately 2.3 hours after oral administration. The Cmax and AUC0-24 values are 263 ng/mL and 2.95 ug/hr/mL, respectively.


Route of Elimination

An estimated 60-70% of indapamide is eliminated in the urine, while 16-23% is eliminated in the feces.


Volume of Distribution

Some sources report an apparent volume of distribution of 25 L for indapamide, while others report a value of approximately 60 L.


Clearance

Indapamide's renal and hepatic clearance values are reported to be 1.71 mL/min and 20-23.4 mL/min, respectively.


5.6 Metabolism/Metabolites

As a result of extensive metabolism in the liver, the majority of indapamide excreted is metabolized, with only 7% remaining unchanged. In humans, as many as 19 distinct indapamide metabolites may be produced, although not all have been identified. There are several metabolic routes through which indapamide may be metabolized, and CYP3A4 is the main enzyme involved in the corresponding hydroxylation, carboxylation, and dehydrogenation reactions. Indapamide can undergo dehydrogenation to form M5, then oxidation to form M4, then further hydroxylation at the indole moiety to form M2. These reactions are facilitated by CYP3A4. Another route of metabolism occurs when indapamide is first hydroxylated to M1 by CYP3A4. M1 then undergoes dehydrogenation to form M3 and is further oxidized to form M2. Hydroxylation of indapamides indole moiety is thought to form the major metabolite (M1), which is less pharmacologically active compared to its parent compound according to animal studies. Indapamide may also undergo epoxidation via CYP3A4 to form a reactive epoxide intermediate. The unstable epoxide intermediate may then undergo dihydroxylation via microsomal epoxide hydrolase to form M6, or glutathione conjugation to form M7.


5.7 Biological Half-Life

Indapamide is characterized by biphasic elimination. In healthy subjects, indapamide's elimination half-life can range from 13.9 to 18 hours. The long half-life is conducive to once-daily dosing.


5.8 Mechanism of Action

Indapamide acts on the nephron, specifically at the proximal segment of the distal convoluted tubule where it inhibits the Na+/Cl- cotransporter, leading to reduced sodium reabsorption. As a result, sodium and water are retained in the lumen of the nephron for urinary excretion. The effects that follow include reduced plasma volume, reduced venous return, lower cardiac output, and ultimately decreased blood pressure. Interestingly, it is likely that thiazide-like diuretics such as indapamide have additional blood pressure lowering mechanisms that are unrelated to diuresis. This is exemplified by the observation that the antihypertensive effects of thiazides are sustained 4-6 weeks after initiation of therapy, despite recovering plasma and extracellular fluid volumes. Some studies have suggested that indapamide may decrease responsiveness to pressor agents while others have suggested it can decrease peripheral resistance. Although it is clear that diuresis contributes to the antihypertensive effects of indapamide, further studies are needed to investigate the medications ability to decrease peripheral vascular resistance and relax vascular smooth muscle.


Drugs in Development

read-more
read-more

Details:

Through the licensing deal for Telmisartan, targeting the Type-1 angiotensin II receptor, the agreement aims to advance hypertension treatment.


Lead Product(s): Telmisartan,Amlodipine,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Widaplik

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Arrotex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 16, 2026

blank

01

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Through the licensing deal for Telmisartan, targeting the Type-1 angiotensin II receptor, the agreement aims to advance hypertension treatment.

Product Name : Widaplik

Product Type : Miscellaneous

Upfront Cash : Undisclosed

March 16, 2026

blank

Details:

Through the licensing deal for Telmisartan, targeting the Type-1 angiotensin II receptor, the agreement aims to advance hypertension treatment.


Lead Product(s): Telmisartan,Amlodipine,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Widaplik

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Ahngook Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 11, 2026

blank

02

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Through the licensing deal for Telmisartan, targeting the Type-1 angiotensin II receptor, the agreement aims to advance hypertension treatment.

Product Name : Widaplik

Product Type : Miscellaneous

Upfront Cash : Undisclosed

March 11, 2026

blank

Details:

Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.


Lead Product(s): Fimasartan,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 19, 2026

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 19, 2026

blank

Details:

Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.


Lead Product(s): Fimasartan,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 19, 2026

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 19, 2026

blank

Details:

Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.


Lead Product(s): Fimasartan,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 19, 2026

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 19, 2026

blank

Details:

Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.


Lead Product(s): Fimasartan,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 19, 2026

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Fimasartan is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 19, 2026

blank

Details:

Olmesartan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies.


Lead Product(s): Olmesartan Medoxomil,Amlodipine,Indapamide,DWC202313,DWC202314

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 05, 2025

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Olmesartan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 05, 2025

blank

Details:

DWJ1622 (Amlodipine) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.


Lead Product(s): Amlodipine,Olmesartan Medoxomil,Indapamide,DWC202313,DWC202314

Therapeutic Area: Genetic Disease Brand Name: DWJ1622

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 03, 2025

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : DWJ1622 (Amlodipine) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.

Product Name : DWJ1622

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 03, 2025

blank
  • Development Update

Details:

Perindoprile is a small molecule drug candidate, which is currently being evaluated for the treatment of Hypertension.


Lead Product(s): Perindoprile,Indapamide,Amlodipine

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Servier

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 02, 2025

blank

09

Instituto Dante Pazzanese de Cardiologia

Country
arrow
PEGS Boston Summit
Not Confirmed

Instituto Dante Pazzanese de Cardiologia

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Perindoprile is a small molecule drug candidate, which is currently being evaluated for the treatment of Hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 02, 2025

blank

Details:

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension.


Lead Product(s): Telmisartan,Amlodipine,Indapamide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: GMRx2

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Biolab Sanus Farmaceutica Ltda

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 02, 2025

blank

10

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

George Medicines

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension.

Product Name : GMRx2

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 02, 2025

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Helvepharm Ag

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Allowed

Registration Country : Switzerland

Perindopril; Indapamidum; Amlodipine

Brand Name : Perindopril Amlodipine Indapamide Zentiva mg

Dosage Form : Tablet

Dosage Strength : 4mg;5mg;1.25mg

Packaging :

Approval Date : 02/07/2021

Application Number : 67958

Regulatory Info : Allowed

Registration Country : Switzerland

Sanofi Company Banner

02

Helvepharm Ag

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Allowed

Registration Country : Switzerland

Perindopril; Indapamidum; Amlodipine

Brand Name : Perindopril Amlodipin Indapamid Zentiva mg

Dosage Form : Tablet

Dosage Strength : 4mg;10mg;1.25mg

Packaging :

Approval Date : 02/07/2021

Application Number : 67958

Regulatory Info : Allowed

Registration Country : Switzerland

Sanofi Company Banner

03

Helvepharm Ag

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Allowed

Registration Country : Switzerland

Perindopril; Indapamidum; Amlodipine

Brand Name : Perindopril Amlodipine Indapamid Zentiva mg

Dosage Form : Tablet

Dosage Strength : 8mg;5mg;2.5mg

Packaging :

Approval Date : 02/07/2021

Application Number : 67958

Regulatory Info : Allowed

Registration Country : Switzerland

Sanofi Company Banner

04

Helvepharm Ag

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

Regulatory Info : Allowed

Registration Country : Switzerland

Perindopril; Indapamidum; Amlodipine

Brand Name : Perindopril Amlodipin Indapamid Zentiva mg

Dosage Form : Tablet

Dosage Strength : 8mg;10mg;2.5mg

Packaging :

Approval Date : 02/07/2021

Application Number : 67958

Regulatory Info : Allowed

Registration Country : Switzerland

Sanofi Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTowa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.

Flag Spain
Digital Content Digital Content

Regulatory Info :

Registration Country : Italy

Indapamide

Brand Name : INDAPAMIDE THINK

Dosage Form : Coated Tablets

Dosage Strength : 2.5 mg

Packaging : 50 UNITS 2.5 MG - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

Towa Pharmaceutical

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTowa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.

Flag Spain
Digital Content Digital Content

Regulatory Info : Authorized

Registration Country : Spain

Indapamide

Brand Name : Indapamida Retard Pensa

Dosage Form : Extended-Release Film Coated Tablet

Dosage Strength : 1.5MG

Packaging :

Approval Date : 12-11-2007

Application Number : 69392

Regulatory Info : Authorized

Registration Country : Spain

Towa Pharmaceutical

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Indapamide

Brand Name : Indapamide

Dosage Form : Indapamide 2,5Mg 50 Combined Oral Use

Dosage Strength : 50 cpr riv 2.5 mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril; Indapamide; Amlodipine

Brand Name : TRIPLIAM

Dosage Form : Film-Coated Tablets

Dosage Strength : 10 mg + 2.5 mg + 5 mg

Packaging : 30 UNITS (8+2.5+5) MG - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril; Indapamide

Brand Name : Cover N combi

Dosage Form : Film Coated Tablet

Dosage Strength : 5mg;1.25mg

Packaging :

Approval Date : 08/04/2010

Application Number : 59104

Regulatory Info : Allowed

Registration Country : Switzerland

blank

10

MYLAN SpA

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

MYLAN SpA

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Perindopril; Indapamide

Brand Name : Perindopril Indapamide

Dosage Form : Perindopril+Indapamide+1,254 Mg 30 Joined' Oral Use

Dosage Strength : 30 CPR 4 mg + 1.25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Bisoprolol Fumarate; Indapamide

Brand Name : Ramipril ; Indapamide ...

Dosage Form : Capsule

Dosage Strength : 5MG; 1.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content

Packaging :

Regulatory Info :

Bisoprolol Fumarate; Indapamide

Dosage : Capsule

Dosage Strength : 5MG; 1.5MG

Brand Name : Ramipril ; Indapamide ...

Approval Date :

Application Number :

Registration Country : Hungary

Egis Pharmaceuticals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Bisoprolol Fumarate; Indapamide

Brand Name : Ramipril ; Indapamide ...

Dosage Form : Capsule

Dosage Strength : 10MG; 1.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content

Packaging :

Regulatory Info :

Bisoprolol Fumarate; Indapamide

Dosage : Capsule

Dosage Strength : 10MG; 1.5MG

Brand Name : Ramipril ; Indapamide ...

Approval Date :

Application Number :

Registration Country : Hungary

Egis Pharmaceuticals

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSince 1980, Octavius Pharma has been empowering lives by delivering trusted healthcare solutions, including DC granules, APIs, and FDFs

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Indapamide

Brand Name : Indapamide

Dosage Form : DC Granules

Dosage Strength : 1.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Octavius Pharma

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSince 1980, Octavius Pharma has been empowering lives by delivering trusted healthcare solutions, including DC granules, APIs, and FDFs

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Indapamide

Dosage : DC Granules

Dosage Strength : 1.5MG

Brand Name : Indapamide

Approval Date :

Application Number :

Registration Country : India

Octavius Pharma

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Indapamide

Brand Name : Indapamide

Dosage Form : Tablet

Dosage Strength : 2.4MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Strides Pharma Science

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Indapamide

Dosage : Tablet

Dosage Strength : 2.4MG

Brand Name : Indapamide

Approval Date :

Application Number :

Registration Country : India

Strides Pharma Science

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Indapamide

Brand Name : Indapamide

Dosage Form : Tablet

Dosage Strength : 2.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Strides Pharma Science

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Indapamide

Dosage : Tablet

Dosage Strength : 2.5MG

Brand Name : Indapamide

Approval Date :

Application Number :

Registration Country : India

Strides Pharma Science

06

Grindeks AS

Latvia
PEGS Boston Summit
Not Confirmed
arrow

Grindeks AS

Latvia
arrow
PEGS Boston Summit
Not Confirmed

Amlodipine; Indapamide; Perindopril

Brand Name :

Dosage Form :

Dosage Strength : 10MG; 2.5MG; 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Latvia

blank

06

Grindeks AS

Latvia
PEGS Boston Summit
Not Confirmed
arrow

Grindeks AS

Latvia
arrow
PEGS Boston Summit
Not Confirmed

Amlodipine; Indapamide; Perindopril

Dosage :

Dosage Strength : 10MG; 2.5MG; 10MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Latvia

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Indapamide

Brand Name : Swilix SR 1.5mg

Dosage Form : TABLET

Dosage Strength : 1.5MG

Packaging : 3x10 Blisters

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Indapamide

Dosage : TABLET

Dosage Strength : 1.5MG

Brand Name : Swilix SR 1.5mg

Approval Date :

Application Number :

Registration Country : India

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril Arginine; Indapamide

Brand Name :

Dosage Form : Tablet

Dosage Strength : 2.5MG; 0.625MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril Arginine; Indapamide

Dosage : Tablet

Dosage Strength : 2.5MG; 0.625MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril Arginine; Indapamide; Amlodipine

Brand Name :

Dosage Form : Tablet

Dosage Strength : 10MG; 2.5MG; 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Perindopril Arginine; Indapamide; Amlodipine

Dosage : Tablet

Dosage Strength : 10MG; 2.5MG; 5MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

10

PRO.MED.CS Praha

Czech Republic
PEGS Boston Summit
Not Confirmed
arrow

PRO.MED.CS Praha

Czech Republic
arrow
PEGS Boston Summit
Not Confirmed

Indapamide

Brand Name : Indap

Dosage Form : Capsule

Dosage Strength : 2.5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Czech Republic

blank

10

PRO.MED.CS Praha

Czech Republic
PEGS Boston Summit
Not Confirmed
arrow

PRO.MED.CS Praha

Czech Republic
arrow
PEGS Boston Summit
Not Confirmed

Indapamide

Dosage : Capsule

Dosage Strength : 2.5MG

Brand Name : Indap

Approval Date :

Application Number :

Registration Country : Czech Republic

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Topical

read-more
read-more

Co-Processed Excipients

read-more
read-more

Taste Masking

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 26807-65-8 / Indapamide API manufacturers, exporters & distributors?

Indapamide manufacturers, exporters & distributors 1

60

PharmaCompass offers a list of Indapamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Indapamide manufacturer or Indapamide supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Indapamide manufacturer or Indapamide supplier.

API | Excipient name

Indapamide

Synonyms

26807-65-8, Noranat, Veroxil, Tertensif, Lozol, Indaflex

Cas Number

26807-65-8

Unique Ingredient Identifier (UNII)

F089I0511L

About Indapamide

A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Manufacturers

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol, including repackagers and relabelers. The FDA regulates Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Suppliers

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol supplier is an individual or a company that provides Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol active pharmaceutical ingredient (API) or Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol finished formulations upon request. The Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers may include Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol API manufacturers, exporters, distributors and traders.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol USDMF

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol DMF (Drug Master File) is a document detailing the whole manufacturing process of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol active pharmaceutical ingredient (API) in detail. Different forms of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol DMFs exist exist since differing nations have different regulations, such as Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol DMF submitted to regulatory agencies in the US is known as a USDMF. Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol USDMF includes data on Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with USDMF on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Drug Master File in Japan (Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol JDMF) empowers Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol JDMF during the approval evaluation for pharmaceutical products. At the time of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with JDMF on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Drug Master File in Korea (Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol. The MFDS reviews the Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol KDMF as part of the drug registration process and uses the information provided in the Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol KDMF to evaluate the safety and efficacy of the drug.

After submitting a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with KDMF on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP of the European Pharmacopoeia monograph is often referred to as a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Certificate of Suitability (COS). The purpose of a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol to their clients by showing that a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP has been issued for it. The manufacturer submits a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP holder for the record. Additionally, the data presented in the Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol DMF.

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with CEP (COS) on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol WC

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol written confirmation (Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol WC) is an official document issued by a regulatory agency to a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol manufacturer, verifying that the manufacturing facility of a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol APIs or Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol finished pharmaceutical products to another nation, regulatory agencies frequently require a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol WC (written confirmation) as part of the regulatory process.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with Written Confirmation (WC) on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol suppliers with NDC on PharmaCompass.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol GMP

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol GMP manufacturer or Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol GMP API supplier for your needs.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CoA

A Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CoA (Certificate of Analysis) is a formal document that attests to Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol's compliance with Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol specifications and serves as a tool for batch-level quality control.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CoA mostly includes findings from lab analyses of a specific batch. For each Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol may be tested according to a variety of international standards, such as European Pharmacopoeia (Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol EP), Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty